Effect of human placental extract on menopausal symptoms, fatigue, and risk factors for cardiovascular disease in middle-aged Korean women

Menopause

Volumn 15, Issue 2, 2008, Pages 296-303

  Kong, Mi Hee ^a   Lee, Eun Ju ^a   Lee, Soon Yong ^a   Cho, Seong Jin ^b   Hong, Young Sun ^c   Park, Sat Byul ^a  

^a Ajou University School of Medicine   (South Korea)

^b Hallym University   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

Author keywords

Fatigue; Human placental extract; Menopausal symptoms

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ESTRADIOL; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLACENTA EXTRACT; PRASTERONE SULFATE; SODIUM CHLORIDE; SOMATOMEDIN C; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; KOREA; LABORATORY TEST; MENOPAUSAL SYNDROME; PATIENT ASSESSMENT; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYMPTOM; VISUAL ANALOG SCALE;

ADULT; CARDIOVASCULAR DISEASES; ESTRADIOL; FATIGUE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; KOREA; MENOPAUSE; MIDDLE AGED; PLACENTAL EXTRACTS; RISK FACTORS;

EID: 40449126776     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181405b74     Document Type: Article

References (46)

1. Sakamoto K, Tonooka M, Abe K, Usami K, Kasahara T. Comparative studies on rat primary cultured and isolated hepatocytes in the evaluation of a therapeutic agent for liver disease. Jpn J Pharmacol 1986;41:424-426.
2. Nakayama S, Kodama K, Oguchi K. A comparative study of human placenta hydrolysate (Laennec) by intravenous or subcutaneous injection on liver regeneration after partial hepatectomy in normal and CCl4-induced cirrhosis rats [in Japanese]. Nippon Yakurigaku Zasshi 1989;94:289-297.
3. Liu KX, Kato Y, Kaku T, Sugiyama Y. Human placental extract stimulates liver regeneration in rats. Biol Pharm Bull 1998;21:44-49.
4. Nakayama S, Yamauchi M, Oguchi K. A comparative study of Laennec by intravenous or subcutaneous injection on CCl4-induced acute or chronic liver injury in rats [in Japanese]. Nippon Yakurigaku Zasshi 1989;94:137-144.
5. Kim HJ, Lee JW, Kim YI, Lee MH. The effect of placental extract on the expression of tyrosinase, TRP-1 and TRP-2 in SK30 melanoma cells. Korean J Dermatol 2003;41:1612-1618.
6. Itho H. Functions and whitening effect of placenta. Fragrance J 1990;6:67-71.
7. Pal P, Mallick S, Mandal SK, et al. A human placental extract: in vivo and in vitro assessments of its melanocyte growth and pigment-inducing activities. Int J Dermatol 2002;41:760-767.
8. Mallick S, Singh SK, Sarkar C, Saha B, Bhadra R. Human placental lipid induces melanogenesis by increasing the expression of tyrosinase and its related proteins in vitro. Pigment Cell Res 2005;18:25-33.
9. Suite M, Quamina DB. Treatment of vitiligo with topical melagenine - a human placental extract. J Am Acad Dermatol 1991;24:1018-1019.
10. Sarkar C, Singh SK, Mandal SK, et al. Human placental protein/ peptides stimulate melanin synthesis by enhancing tyrosinase gene expression. Mol Cell Biochem 2006;285:133-142.
11. Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke 2001;32:1104-1111.
12. Matthews KA, Wing RR, Kuller LH, Meilahn EN, Plantinga P. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch Intern Med 1994;154:2349-2355.
13. Lyndaker C, Hulton L. The influence of age on symptoms of perimenopause. J Obstet Gynecol Neonatal Nurs 2004;33:340-347.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
15. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
16. Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes 2003;1:28.
17. Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes 2004;2:45.
18. Hauser GA, Huber IC, Keller PJ, Lauritzen C, Schneider HP. Evaluation of climacteric symptoms (Menopause Rating Scale) [in German]. Zentralbl Gynakol 1994;116:16-23.
19. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric 2000;3:59-64.
20. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
21. Kleinman L, Zodet MW, Hakim Z, et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000;9:499-508.
22. Chung KI, Song CH. Clinical usefulness of fatigue severity scale for patients with fatigue, and anxiety or depression. Korean J Psychosom Med 2001;9:164-173.
23. Bates DW, Schmitt W, Buchwald D, et al. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med 1993;153:2759-2765.
24. Kim CH, Shin HC, Won CW. Prevalence of chronic fatigue and chronic fatigue syndrome in Korea: community-based primary care study. J Korean Med Sci 2005;20:529-534.
25. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res 1993;37:147-153.
26. Devanur LD, Kerr JR. Chronic fatigue syndrome. J Clin Virol 2006;37:139-150.
27. Sur TK, Biswas TK, Ali L, Mukherjee B. Anti-inflammatory and antiplatelet aggregation activity of human placental extract. Acta Pharmacol Sin 2003;24:187-192.
28. Banerjee KK, Bishayee A, Chatterjee M. Anti-inflammatory effect of human placental extract: a biochemical mechanistic approach. Riv Eur Sci Med Farmacol 1992;14:361-366.
29. Biswas TK, Auddy B, Bhattacharya NP, Bhattacharya S, Mukherjee B. Wound healing activity of human placental extracts in rats. Acta Pharmacol Sin 2001;22:1113-1116.
30. Shukla VK, Rasheed MA, Kumar M, Gupta SK, Pandey SS. A trial to determine the role of placental extract in the treatment of chronic nonhealing wounds. J Wound Care 2004;13:177-179.
31. Chakraborty PD, Bhattacharyya D. Isolation of fibronectin type III like peptide from human placental extract used as wound healer. J Chromatogr B Analyt Technol Biomed Life Sci 2005;818:67-73.
32. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2002;CD003807.
33. Kaushal V, Verma K, Manocha S, Hooda HS, Das BP. Clinical evaluation of human placental extract (placentrex) in radiation-induced oral mucositis. Int J Tissue React 2001;23:105-110.
34. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10:6342S-6346S.
35. Shibasaki T, Odagiri E, Shizume K, Ling N. Corticotropin-releasing factor-enlike activity in human placental extracts. J Clin Endocrinol Metab 1982;55:384-386.
36. Carotti D, Allegra E. An approach to chemical characterization of human placental extracts: proteins, peptides, and amino acids analyses. Physiol Chem Phys 1981;13:129-136.
37. Wilbur J, Shaver J, Kogan J, Buntin M, Wang E. Menopausal transition symptoms in midlife women living with fibromyalgia and chronic fatigue. Health Care Women Int 2006;27:600-614.
38. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001;104:63-67.
39. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-2825.
40. Hutton RA, Dandona P, Chow FP, Craft IL. Inhibition of platelet aggregation by placental extracts. Thromb Res 1980;17:465-471.
41. Wolf HK, Zarnegar R, Oliver L, Michalopoulos GK. Hepatocyte growth factor in human placenta and trophoblastic disease. Am J Pathol 1991;138:1035-1043.
42. Saito S, Sakakura S, Enomoto M, Ichijo M, Matsumoto K, Nakamura T. Hepatocyte growth factor promotes the growth of cytotrophoblasts by the paracrine mechanism. J Biochem (Tokyo) 1995;117:671-676.
43. Corson SL, Richart RM, Caubel P, Lim P. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17ß-estradiol and norgestimate on endometrial histology. Int J Fertil Womens Med 1999;44:279-285.
44. Kurman RJ, Felix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000;96:373-379.
45. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079.
46. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.